Myocardial Infarction News and Research

RSS

European Commission approves MICARDIS medication for CV protection

MICARDIS® is the first treatment in its class to be approved for this indication. The EMEA approval is the second major milestone for MICARDIS® in cardiovascular protection. It follows the approval by the US FDA for the reduction of the risk of myocardial infarction (heart attack), stroke, or death from cardiovascular (CV) causes in patients 55 years of age or older at high risk of developing major CV events who are unable to take ACE inhibitors.

27 Nov 2009

MICARDIS receives Health Canada approval to reduce the risk of non-fatal stroke

MICARDIS(R) (telmisartan) has received Health Canada approval to reduce the risk of non-fatal stroke or non-fatal myocardial infarction in patients 55 years or older at high risk of developing major cardiovascular events who cannot tolerate an angiotensin converting enzyme (ACE) inhibitor.

26 Nov 2009

Study finds no significant difference in hospital angioplasty volume and death rates in patients with myocardial infarction

A study based on a contemporary registry of patients with myocardial infarction (heart attack) indicates that even though hospitals that perform a higher number of angioplasties are more likely to follow evidence-based guidelines and have shorter times to the angioplasty procedure, there appears to be no significant difference in outcomes such as length of hospital stay or risk of death, according to a study in the November 25 issue of JAMA.

25 Nov 2009

AmKor and Hengdian Group sign license agreement to develop and market new drug candidate in China

AmKor (AmKor Pharma, Inc.) and Hengdian Group (Hengdian Group Ltd) today announced the signing of licensing agreement for further development and commercialization of Neu2000 in China.

24 Nov 2009

Texas Court dismisses all claims against Merck in VIOXX-related lawsuit

Merck said today that Travis County, Texas District Court Judge Scott H. Jenkins granted Merck's motion for summary judgment, dismissing all claims in a VIOXX-related lawsuit filed on behalf of the State of Texas.

23 Nov 2009

New Drug Application for ticagrelor submitted to the FDA

AstraZeneca today announced it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for ticagrelor, an investigational oral antiplatelet treatment for the reduction of major adverse cardiac events in patients with acute coronary syndrome (ACS).

23 Nov 2009

Increased computerization in U.S. hospitals hasn't made them cheaper or more efficient, say researchers

The increased computerization in U.S. hospitals hasn't made them cheaper or more efficient, Harvard researchers say, although it may have modestly improved the quality of care for heart attacks.

20 Nov 2009

Updated clinical guidelines on Effient treatment for ACS patients

Effient® (prasugrel) tablets, a new antiplatelet medicine, was added as a treatment option in two clinical guideline updates: one for patients receiving percutaneous coronary intervention (PCI) and a second one for patients with ST elevation myocardial infarction (STEMI), or severe heart attack.

19 Nov 2009

Publicly released report cards do not appear to improve hospitals' performance, says new study

An analysis of quality of cardiac care following the public release of data on measures of care at hospitals in Ontario, Canada, did not result in significant systemwide improvement in hospitals' performance on most quality of care indicators, according to a study to be published in the December 2 issue of JAMA. The study is being released early online because of its presentation at an American Heart Association scientific conference.

19 Nov 2009

Results from Phase IIa clinical trial evaluating VT-111 reported by Viron Therapeutics

Viron Therapeutics Inc., a biotechnology company pioneering the development of immune-modulating protein therapeutics derived from pathogens, today reported results from a Phase IIa clinical trial evaluating VT-111 (Serp-1), an anti-inflammatory protein derived from the myxoma virus.

19 Nov 2009

CRESTOR reduces major cardiovascular events in women by 46%

A new analysis of the JUPITER trial, released today at the American Heart Association meeting in Orlando, Florida, demonstrates that CRESTOR (rosuvastatin calcium) 20mg reduced first major cardiovascular events by 46%.

18 Nov 2009

Consortium to define new modalities for treating hypertension and associated vascular complications

Top Institute Pharma has formed a consortium with Actelion Pharmaceuticals Ltd, Erasmus Medical Centre and Maastricht University to define new modalities for the treatment of hypertension (high blood pressure) and associated vascular complications such as heart and kidney failure, myocardial infarction and stroke.

17 Nov 2009

Sudden cardiac death more predictable in men than women

A woman who suffers sudden cardiac arrest is significantly less likely than a man to exhibit the decrease in the heart's pumping ability that is widely recognized as a precursor, says a new study in the Nov. 24 Journal of the American College of Cardiology.

17 Nov 2009

China Medicine reports total revenues of $19.2M for the third quarter of 2009

China Medicine Corporation, a developer and a leading distributor of prescription and over-the-counter pharmaceuticals, traditional Chinese medicines (TCM), nutritional and dietary supplements, and medical devices and medical formulations, today announced its third quarter 2009 results.

16 Nov 2009

Aspirin doses have beneficial effects for patients with heart diorders: Study

On Sunday, November 15, 2009, Florida Atlantic University (FAU) researcher Charles H. Hennekens, M.D., the first Sir Richard Doll Research Professor in the Charles E. Schmidt College of Biomedical Science will present at the American Heart Association's Annual Scientific Sessions meeting in Orlando, FL, the first data in humans to show that all doses of aspirin used in clinical practice increase nitric oxide.

16 Nov 2009

New reversible oral anti-platelet medication had fewer cardiac events in heart attack patients

Acutely ill heart attack patients who received both aspirin and a new reversible oral anti-platelet medication had fewer cardiac events than patients on aspirin and the most commonly used, irreversible anti-platelet drug, researchers reported in a late-breaking clinical trial presentation at the American Heart Association's Scientific Sessions 2009.

16 Nov 2009

Higher levels of phosphorus in blood linked to increased calcification of coronary arteries, says study

Higher levels of phosphorus in the blood are linked to increased calcification of the coronary arteries— a key marker of heart disease risk, according to a study in an upcoming issue of Clinical Journal of the American Society of Nephrology (CJASN). "This may help to explain why even early-stage chronic kidney disease (CKD) is associated with increased cardiovascular risk that is not otherwise explained by traditional risk factors," comments Katherine R. Tuttle, MD (Providence Medical Research Center, Spokane, WA).

6 Nov 2009

Poor managerial leadership linked with the amont of sick leave taken at workplace

Perceived poor managerial leadership increases not only the amount of sick leave taken at a workplace, but also the risk of sickness amongst employees later on in life. The longer a person has had a "poorer" manager, the higher his or her risk of for example suffering a heart attack within a ten-year period, according to a new thesis from the Swedish medical university Karolinska Institutet.

2 Nov 2009

Alnylam Pharmaceuticals announces participation in a $2.4M cardiovascular disease research grant

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today its participation in a $2.4 million research grant awarded to the University of Pennsylvania under the “American Recovery and Reinvestment Act of 2009”. The new grant will fund research over two years in the laboratories of Daniel Rader, M.D. of the University of Pennsylvania School of Medicine, Sekar Kathiresan, M.D. of Massachusetts General Hospital (MGH) and Harvard Medical School, and Alnylam.

29 Oct 2009

CNS Protein Therapeutics changes its corporate name to Amarantus Therapeutics

CNS Protein Therapeutics, Inc., a privately held biotechnology company developing first-in-class disease–modifying treatments that address the underlying cause of cell death associated with a wide range of diseases, has completed a corporate name change to Amarantus Therapeutics, Inc. (“Amarantus”) and appointed prominent biotechnology industry executive, Martin D. Cleary, as Chief Executive Officer.

29 Oct 2009

Myocardial Infarction News and Research

European Commission approves MICARDIS medication for CV protection

MICARDIS receives Health Canada approval to reduce the risk of non-fatal stroke

Study finds no significant difference in hospital angioplasty volume and death rates in patients with myocardial infarction

AmKor and Hengdian Group sign license agreement to develop and market new drug candidate in China

Texas Court dismisses all claims against Merck in VIOXX-related lawsuit

New Drug Application for ticagrelor submitted to the FDA

Increased computerization in U.S. hospitals hasn't made them cheaper or more efficient, say researchers

Updated clinical guidelines on Effient treatment for ACS patients

Publicly released report cards do not appear to improve hospitals' performance, says new study

Results from Phase IIa clinical trial evaluating VT-111 reported by Viron Therapeutics

CRESTOR reduces major cardiovascular events in women by 46%

Consortium to define new modalities for treating hypertension and associated vascular complications

Sudden cardiac death more predictable in men than women

China Medicine reports total revenues of $19.2M for the third quarter of 2009

Aspirin doses have beneficial effects for patients with heart diorders: Study

New reversible oral anti-platelet medication had fewer cardiac events in heart attack patients

Higher levels of phosphorus in blood linked to increased calcification of coronary arteries, says study

Poor managerial leadership linked with the amont of sick leave taken at workplace

Alnylam Pharmaceuticals announces participation in a $2.4M cardiovascular disease research grant

CNS Protein Therapeutics changes its corporate name to Amarantus Therapeutics

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence

Latest News